Tag Archives: T-cells

Immunotherapy

Posted on December 21, 2014 by Team Captain

I am not sure how many people outside of the cancer research community know this, but it is well recognized that the human body is equipped to fight off cancer on its own. The same immune system that we have … Continue reading →

Posted in Cancer, Childhood Cancer, Pediatric Cancer, Rare Disease, Uncategorized | Tagged acute lymphoblastic leukemia, ALL CLL, American Society of Hematology, autoimmune disease, biotech, Bristol-Meyers Squibb, CAR, CAR T, CART, checkpoint inhibitor, chemotherapy, Children's Hospital of Philadelphia, chimeric antigen receptor, cytokines, DNA, Dr. Stephen Grupp, EGFG, FDA, Gardasil, HIV Aids, immunosupressive, immunotherapy, interferon, interleukins, Keytruda, Laurie Orloski, Leukemia, Melanoma, Merck, metastatic disease, molecularly targeted agents, New England Journal of Medicine, nivolumab, Novartis Pharmaceuticals, Opdivo with r symbol, PD-1, pembrolizumab, personalized medicine, pharma, pharmaceutical, small-molecule inhibitors, spontaneous remission, T-cells, toxicity, tyrosine kinase inhibitors (TKIs), University of Pennsylvania, vaccines | 1 Comment

Five year cure, …really?

Posted on November 11, 2014 by Team Captain

Five-year relative survival rates describe the percentage of patients with cancer that are alive five years after their disease is diagnosed. Use of 5-year survival statistics is more useful in aggressive cancers that have a shorter life expectancy following diagnosis (such … Continue reading →